Investor Presentation Q1 2022

12 Investor presentation First three months of 2022 Semaglutide 2.0 mg label reflects superior HbA1c reduction with similar number of GI side-effects as semaglutide 1.0 mg Profile Results reflected in the approved label for OzempicⓇ 2.0 mg Approved for treatment of type 2 diabetes in adults Reduce the risk of major adverse cardiovascular events in adults with type 2 diabetes and established cardiovascular disease OZEMPİC® (semaglutide) injection For Single Patient Use Only 8 mg/3 mL (2.68 mg/mL) Prefilled pen Pen delivers doses in 2 mg increments only For subcutaneous use only Use OZEMPIC once weekly NDC QLED 4772-11 List: 47211 OZEMPIC® (semaglutide) injection For Single Patient Use Only Pen delivers doses in NDC 0169-4772-12 List 477212 OZEMPİC (Injection -0- 0ma novo nordisk Efficacy • Safety Novo NordiskⓇ Statistically significant HbA1c reduction of 2.1%* in SUSTAIN FORTE Weight reduction of 6.4 kg* in SUSTAIN FORTE Appears to have a safe and well-tolerated profile • Similar number of gastrointestinal side-effects as OzempicⓇ 1.0 mg Overall withdrawal rate below 4% GI: gastrointestinal *Based on the treatment policy estimand. When using the trial product estimand, there was a statistically significant reduction in HbA1c of 2.2% and statistically significant reduction in body weight of 6.9 kg. Note: OzempicⓇ package and pen based on intended presentation

View entire presentation